Youngevity University of Manitoba Study

Youngevity International (YGYI) Announces Results ofYoungevity Research Studies Performed by the Richardson Center for Functional Foods and Nutraceuticals – University of Manitoba

San Diego, CA – May 28, 2014 – Youngevity International, Inc. (OTCQX: YGYI) (www.YGYI.com), a global direct marketer of lifestyle and nutritional products and gourmet coffee, announced today the exciting results of researchstudies performed at the prestigious Richardson Center for Functional Foods and Nutraceuticals (RCFFN) at the University of Manitoba (www.rcffn.ca).

The RCFFN is one of the most advanced bioprocessing and product development facilities in the world that focuses on the research, discovery, and development of innovative functional foods and nutraceuticals. The research team at the RCFFN evaluated the safety and health benefits of the following Youngevity signature products; Beyond Tangy Tangerine 2.0 and the Healthy Start Pak 2.0, which consists of the Beyond Tangy Tangerine 2.0, Beyond OsteoFx 2.0, and Ultimate Essential Fatty Acids.

The study was overseen by Dr. Peter Jones, Director of the RCFFN and one of the world’s foremost researchers in dietary and nutraceutical determinants in the control of fat, energy metabolism, and various other critical health issues. Additionally, the study was conducted by Dr. Ramprasath Vanu Ramkumar, Adjunct Professor and Research Associate for the Department of Human Nutritional Sciences at the University of Manitoba.

“When initially developing the study outline for Youngevity, it was critical to investigate the important areas where the products could be of benefit and demonstrate a high level of safety, I believe we have accomplished that, these were very well thought out studies,” said Dr. Peter Jones, RCFFN Director.

Youngevity Research Study Results:

Safety: RCFFN tested various levels of organ functions and metabolism to demonstrate the safety of Beyond Tangy Tangerine 2.0, Beyond OsteoFx 2.0, and Ultimate Essential Fatty Acids. The biochemical indicators and measurement showed normal functioning and metabolism of the liver, kidneys, and heart after supplementation with Beyond Tangy Tangerine 2.0 and the Healthy Start Pak 2.0 demonstrate no adverse reactions to these organs.

Weight Loss: Consumption of the Beyond Tangy Tangerine 2.0 as well as the Healthy Start Pak 2.0 significantly reduced the absolute weights of White Adipose Tissue (WAT) as well as WAT weight percentage of whole body weight. The study showed a significant reduction in adipose tissue weight and body fat mass.

Bone Health: Significant reductions in plasma concentrations of Alkaline Phosphatase, ALKP, an enzyme that promotes breakdown of bone were observed along with increases in concentrations of the bone building minerals, calcium and phosphorus.

Support for Normal Inflammatory Response: Inflammation was induced in the animal models by feeding them a high fat and sugar diet that triggers the Interleukin-6 inflammatory marker. After supplementation with both the Beyond Tangy Tangerine 2.0 and Healthy Start Pak 2.0 a significant reduction of the inflammatory marker was observed demonstrating support for normal inflammatory responses when placed under stressful conditions.

“It’s very important that studies such as these are done in a unbiased, highly respected, academic setting. Consumers can feel confident in the results of these studies because of the “arms length” relationship that RCFFN had withYoungevity, we reported everything we found,” said Dr. Ramprasath Vanu Ramkumar, University of Manitoba Associate Professor.

“Building on the previous research Youngevity performed with Clemson University, the RCFFN study results further substantiate the incredible potential value and benefit our consumers can receive with the Youngevity products.Youngevity is one of the few companies that provide such comprehensive research along with their products and we are proud to do so,” said Sanjeev Javia, Youngevity Scientific Advisory Board Member.

“For over 15 years, Youngevity has been committed to science backed nutrition and providing the highest quality nutrients, dietary supplements, and wellness products to our distributors and customers,” said Steve Wallach, CEO and Chairman of Youngevity. “We are very excited and proud of the research results achieved on our signature products by the world-class researchers at the prestigious Richardson Center for Functional Foods and Nutraceuticals. The research studies performed on our products at Clemson University in 2012 and the University of Manitoba provide further support for the value and health benefits that we believe can be obtained from our products and Youngevity’s dedication to research and innovation.”

About Youngevity International Inc.

Youngevity International Inc., (OTCQX: YGYI) (www.YGYI.com) is a fast-growing, innovative, multi-dimensional company that offers a wide range of consumer products and services, primarily through person-to-person selling relationships that comprise a “network of networks.” The Company also is a vertically-integrated producer of the finest coffees for the commercial, retail and direct sales channels. The Company was formed after the merger of YoungevityEssential Life Sciences (www.youngevity.com) and Javalution Coffee Company in the summer of 2011. The company was formerly known as AL International, Inc. and changed its name to Youngevity International Inc. in July 2013.

Safe Harbor Statement

This release includes forward-looking statements on our current expectations and projections about future events, including our continued growth. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “encouraged” and similar expressions. The forward looking statements include statements regarding our expected future growth, international expansion and improved profit. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict such as our ability to continue our financial performance. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Youngevity Clemson Study

AL International (JCOF) Announces Results of Youngevity Clinical Research Studies Performed by Clemson University – Institute of Nutraceutical Research

San Diego, CA – January 25, 2013 – Youngevity Essential Life Sciences (www.youngevity.com), a wholly-owned subsidiary of AL International, Inc. (OTC Pink: JCOF) (www.alintjcof.com), a fast growing, innovative, global direct marketer of healthy lifestyle and nutritional products and gourmet fortified coffee, announced today the exciting results of a series of clinical research studies performed by Clemson University – Institute of Nutraceutical Research (“INR”).

The INR is a national leader in nutritional research and one of the most highly regarded organizations in the field of phytonutrients, vitamins and minerals. The goals of the INR are to develop greater confidence in product quality, effectiveness, and enhance consumer demand for quality nutraceutical products.

The clinical studies were performed to identify the potential benefits of Youngevity’s signature core products, Beyond Tangy Tangerine and Ultimate Classic. Youngevity’s mission was to truly understand and clinically substantiate the health promoting benefits of these two products. Individually, each product targets specific areas, needs, and nutritional deficiencies of the body.

Multiple studies were recommended by Clemson University scientists to provide a comprehensive evaluation of the Youngevity products. Specific biomarkers were chosen to study in the areas of safety, inflammation, and when Beyond Tangy Tangerine and Ultimate Classic were administered to cancer cell cultures.

Youngevity Clinical Research Study Highlights:

  • Dietary supplement safety is the most highly regarded aspect of any of the Youngevity various products and has become synonymous with the Youngevity name and brand. Although Youngevity only uses nutrients that are absolutely needed by the body and in forms that are highly bioavailable, Youngevity felt it was important to show empirically the range and degree of safety through looking at (3) factors – Genotoxicity, Anti-Genotoxicity, and Anti-Mutagenicity. The results of the experiments showed that Beyond Tangy Tangerine and Ultimate Classic at various concentrations did not show any genotoxicity.
  • When Beyond Tangy Tangerine and Ultimate Classic were administered to healthy human cell lines; they did not induce or create any inflammatory response in levels above and below the recommended dosage. Beyond Tangy Tangerine and Ultimate Classic showed inflammation protective properties and heightened the body’s protective responses to possible inflammation.
  • When Beyond Tangy Tangerine and Ultimate Classic were administered to healthy human colon cells; there was no significant death of healthy human cells compared to cancerous colon cells. Ultimate Classic killed 95% of cancerous colon cells, 65% of cancerous liver cells, 65% of cancerous stomach cells, and 30% of cancerous breast cells. Beyond Tangy Tangerine killed 60% of cancerous colon cells, 65% of cancerous liver and stomach cells, and 30% of cancerous breast cells.
  • Beyond Tangy Tangerine and Ultimate Classic both exhibited efficient inhibition on proliferation of cancerous cells at the recommended dosage levels. Both products showed there was inhibition of the growth of more cancerous cells, preventing further malignant multiplication and growth of unhealthy cells.

The Clemson University studies have provided Youngevity greater confidence in their products, scientist, formulators, and manufacturing processes and helped to understand some of the pathways the Youngevity products may be working through in order to provide these benefits.

AL International CEO, Steve Wallach, adds, “At Youngevity we have always sought to provide high quality and safe products, these studies have added to the assurance we have in all of the Youngevity products.”

About Youngevity(R) Essential Life Sciences

Youngevity Essential Life Sciences (www.youngevity.com ), headquartered in San Diego, CA, is a nutrition and lifestyle-related services company dedicated to promoting vibrant health and flourishing economics. Founded in 1997 by Drs. Joel Wallach, DVM, ND, and Ma Lan, MD, as AL Global, Inc., the company adopted the name Youngevity in 2006. Youngevity is the only direct selling company to have a qualified FDA Health Claim. Dr. Wallach’s work has been published in more than 70 peer-reviewed and referenced scientific journals and books.

About AL International

AL International, Inc. (OTC Pink: JCOF) (www.alintjcof.com) is a fast-growing, innovative, multi-dimensional company that offers a wide range of consumer products and services, primarily through person-to-person selling relationships that comprise a “network of networks.” The company also is a vertically-integrated producer of the finest coffees for the commercial, retail and direct sales channels. AL International was formed after the merger of Youngevity Essential Life Sciences (www.youngevity.com) and Javalution Coffee Company in the summer of 2011.

Safe Harbor Statement

This release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.